Bloomberg Business
Published on Jul 24, 2015
July 24 -- What’s good for patients is also good for business. The painkiller market alone is worth $18 billion a year. The drug industry is pressing ahead with research into genetic irregularities. The FDA is expected to approve a cholesterol-lowering treatment from Sanofi and Regeneron Pharmaceuticals based on the rare gene mutation of an aerobics instructor with astoundingly low cholesterol levels. Bloomberg's Caroline Chen has more on "Bloomberg Markets."
No comments:
Post a Comment